109170 ⎘
Structure or type of the nucleic acid; Chemical structure of the sugar 2'-O-R Modification
Compositions and their uses directed to huntingtin
#1202INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1203NEUROFILAMENT PROTEIN FOR GUIDING THERAPEUTIC INTERVENTION IN AMYOTROPHIC LATERAL SCLEROSIS
#1204POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF
#1205Targeting Ligands
#1206SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES
#1207METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MLH1 ACTIVITY
#1208ANDROGEN RECEPTOR NUCLEIC ACIDS AND USES THEREOF
#1209PRODUCTS AND COMPOSITIONS
#1210BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
#1211NOVEL RNA COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL8
#1212Compounds and methods for reducing prion expression
#1213RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF
#1214METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER
#1215Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#1216An lncRNA integrates a DNA-PK-mediated DNA damage response and vascular senescence
#1217Oligonucleotides for treatment of angiopoietin like 4 (ANGPTL4) related diseases
#1218METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE
#1219AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#1220NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
#1221OLIGONUCLEOTIDE-MEDIATED SENSE CODON REASSIGNMENT
#1222COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE
#1223Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer
#1224POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF
#1225OLIGONUCLEOTIDES TO TREAT EYE DISEASE
#1226Antisense Compounds Targeting Genes Associated with Cystic Fibrosis
#1227Splice-switching oligonucleotides and methods of use
#1228VDAC1 SILENCING MOLECULES AND USE THEREOF
#1229METHODS AND COMPOSITIONS FOR TREATMENT OF FRONTOTEMPORAL DEMENTIA
#1230Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
#1231COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#1232Monocarboxylate transporter (MCT) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
#1233Modulators and modulation of the receptor for advanced glycation end-products RNA
#1234COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF PROTEIN C (PROC) GENES
#1235OLIGONUCLEOTIDE FORMULATION METHOD
#1236Dosages and methods for delivering lipid formulated nucleic acid molecules
#1237Oligomers
#1238Reducing Prominin2-Mediated Resistance to Ferroptotic Cell Death
#1239RNA DRUGS AND METHOD OF TREATING AGE-RELATED DISEASE
#124017ß-Hydroxysteroid Dehydrogenase Type 13 (HSD17B13) iRNA Compositions And Methods Of Use Thereof
#1241Compositions and methods for inhibiting ALDH2 expression
#1242Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
#1243Methods and Compositions for the ADAR-Mediated Editing of SERPINA1
#1244Multi-Targeting Nucleic Acid Constructs Composed Of Multiple Oligonucleotides That Modulate Gene Expression Through Complimentary Interactions With Targets
#1245OLIGONUCLEOTIDES FOR MODULATING MYH7 EXPRESSION
#1246Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#1247Methods for treating or preventing ophthalmological conditions
#1248OLIGONUCLEOTIDES FOR SNCA MODULATION
#1249OLIGONUCLEOTIDES FOR MAPT MODULATION
#1250MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING
#1251Soluble TNF Receptors and Their Use in Treatment of Disease
#1252Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
#1253COMPOUNDS AND METHODS FOR REDUCING FXI EXPRESSION
#1254OLIGONUCLEOTIDE MEDIATED NO-GO DECAY
#1255CARGO LOADED EXTRACELLULAR VESICLES
#1256OLIGONUCLEOTIDES FOR MSH3 MODULATION
#1257Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
#1258IMMUNOTHERAPY OF CANCER
#1259Compositions and methods for inhibiting expression of the LECT2 gene
#1260Substances for targeting various selected organs or tissues
#1261GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
#1262Compositions and methods for prevention of bladder fibrosis
#1263Dual-acting siRNA based modulation of C9orf72
#1264Mixed Tricyclo-DNA, 2'-Modified RNA Oligonucleotide Compositions and Uses Thereof
#1265Single-stranded RNA-editing oligonucleotides
#1266ANTISENSE NUCLEIC ACIDS
#1267Methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles
#1268Aptamer therapeutics useful in the treatment of complement-related disorders
#1269MINIATURIZED HAIRPIN RNAi TRIGGERS (mxRNA) AND METHODS OF USES THEREOF
#1270CCR7 aptamers and uses thereof
#1271Compositions and methods for increasing expression of SCN2A
#1272MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
#1273Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
#1274POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF
#1275ANTISENSE OLIGONUCLEOTIDE (ASO) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES
#1276Nucleic Acid Compounds for Binding Immunoglobulin G
#1277SERPINA1 iRNA compositions and methods of use thereof
#1278Compositions and methods for modulating neuronal excitability and motor behavior
#1279Compounds and Methods for Modulation of Transcript Processing
#1280Angiotensinogen (AGT) iRNA compositions and methods of use thereof
#1281Antisense oligomers for treatment of conditions and diseases
#1282MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA
#1283RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
#1284Compositions of Asymmetric Interfering RNA and Uses Thereof
#1285Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#1286Compositions and methods of treating muscle dystrophy
#1287COMPOSITIONS AND METHODS FOR THE TREATMENT OF COMPLICATIONS AND DISORDERS RELATING TO VON WILLEBRAND FACTOR
#1288Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
#1289Methods for treating hypercholesterolemia
#1290Oligonucleotides targeting frataxin and related methods
#1291ANTISENSE NUCLEIC ACIDS
#1292Methods for treating hepatitis B infection
#1293Methods and compositions for targeting PD-L1
#1294Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
#1295Compounds and methods for modulating UBE3A-ATS
#1296CHEMICALLY-MODIFIED GUIDE RNAS TO IMPROVE CRISPR-CAS PROTEIN SPECIFICITY
#1297IL-1 BETA TARGETING SPHERICAL NUCLEIC ACIDS
#1298METHODS AND COMPOSITIONS FOR TARGETING PD-L1
#1299Artificial exosome composition and related methods
#1300TREATMENT OF CARDIOMYOPATHY THROUGH MODULATION OF HYPOXIA-INDUCED eRNA ACTIVITY
#1301SMAC/Diablo inhibitors useful for treating cancer
#1302Complement component C3 iRNA compositions and methods of use thereof
#1303TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1304Oligonucleotide comprising an inosine for treating DMD
#1305SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1306OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
#1307LINKAGE MODIFIED OLIGOMERIC COMPOUNDS
#1308Compounds and methods for increasing STMN2 expression
#1309Antisense oligonucleotides and their use for treating Pendred syndrome
#1310Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1311Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
#1312Oligonucleotides for modulating SCN9A expression
#1313PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
#1314BETA CATENIN NUCLEIC ACID INHIBITOR MOLECULE
#1315Selective antisense compounds and uses thereof
#1316Compositions and methods for the treatment of expanded repeat-associated disorders
#1317RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1318STEM-LOOP COMPOSITIONS AND METHODS FOR INHIBITING INTERLEUKIN-8
#1319OLIGONUCLEOTIDES FOR CONTROLLING TAU SPLICING, AND USES THEREOF
#1320RIG-I Agonists and Methods of Using Same
#1321MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#1322LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1323POLYNUCLEOTIDE AGENTS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) AND METHODS OF USE THEREOF
#1324Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene Editing
#1325ANTISENSE NUCLEIC ACIDS
#1326METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME
#1327LNA BASED NANODEVICE
#1328COMPOSITIONS FOR DELIVERY OF CARGO TO CELLS
#1329COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
#1330Gamma herpesvirus circular RNA
#1331Compositions and methods for modulating growth hormone receptor expression
#1332Non-liposomal systems for nucleic acid delivery
#1333MYOCARDIAL DYSFUNCTION THERAPEUTIC AGENT
#1334METHODS FOR DETERMINING THE PRESENCE OR RISK OF DEVELOPING FACIOSCAPULOHUMERAL DYSTROPHY (FSHD)
#1335TEMPERATURE CONTROLLED DNA POLYMERASE INHIBITORS
#1336ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
#1337Antisense nucleic acids
#1338Method of allele specific silencing for the treatment of autosomal dominant Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
#1339Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
#1340Targeting ligands for therapeutic compounds
#1341Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
#1342Transgene cassettes designed to express a human MECP2 gene
#1343Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
#1344MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
#1345MODULATORS OF ENaC EXPRESSION
#1346Systems and methods for gene modification
#1347SYNTHETIC RNAS AND METHODS OF USE
#1348Nucleic acid-polypeptide compositions and uses thereof
#1349ANTISENSE NUCLEIC ACIDS
#1350Glucokinase (GCK) iRNA compositions and methods of use thereof
#1351Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1352Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1353Modulation of factor 11 expression
#1354METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER
#1355TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES
#1356Modulation of alternative MDM2 splicing
#1357Compositions and Methods for Hydroxyacid Oxidase 1 (HAO1) Gene Editing for Treating Primary Hyperoxaluria Type 1 (PH1)
#1358Agents useful in treating facioscapulohumeral muscular dystrophy
#1359AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#1360MRNA driven expression of RNA editors for treatment of pathologies
#1361COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE
#1362Modulation of gene expression and screening for deregulated protein expression
#1363Modulators of EZH2 expression
#1364siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS
#1365Gene editing methods with increased knock-in efficiency
#1366REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
#1367Aptamers for targeted activation of T cell-mediated immunity
#1368SiRNAs with vinylphosphonate at the 5′ end of the antisense strand
#1369Antisense nucleic acids
#1370Selective Antisense Compounds and Uses Thereof
#1371Antisense oligonucleotides useful in treatment of Pompe disease
#1372RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF
#1373Two-tailed self-delivering siRNA
#1374Modulation of Huntington expression
#1375PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER
#1376Treatment of Fuchs' endothelial corneal dystrophy
#1377Reverse transcriptase for nucleic acid sequencing
#1378COMPOSITIONS AND METHODS
#1379Three-dimensional self-assembled nucleic acid nanoparticles and use thereof
#1380COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
#1381Oligonucleotides for modulating Tau expression
#1382Uses for prevention or treatment of brain diseases using microRNA
#1383Antisense oligonucleotides for the treatment of usher syndrome type 2
#1384Modified double-stranded donor templates
#1385O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES
#1386Antisense oligonucleotides for the treatment of Stargardt disease
#1387MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes
#1388RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
#1389MODULATORS OF GROWTH HORMONE RECEPTOR
#1390OLIGONUCLEOTIDE DERIVATIVE OR SALT THEREOF
#1391RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1392MicroRNA Compounds and Methods for Modulating MIR-122
#1393RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
#1394Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
#1395BRANCHED LIPID CONJUGATES OF siRNA FOR SPECIFIC TISSUE DELIVERY
#1396Compositions and methods for modulating MECP2 expression
#1397Method of nonspecific target capture of nucleic acids
#1398RNAi agents for hepatitis B virus infection
#1399Angiotensinogen (AGT) iRNA compositions and methods of use thereof
#1400Modified oligonucleotides for use in treatment of tauopathies
#1401Modified Oligonucleotides for Treatment of Polycystic Kidney Disease
#1402Modulation of transthyretin expression
#1403Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
#1404Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Reduction
#1405Modified Guide RNAs for Gene Editing
#1406Therapeutic oligonucleotides
#1407Compositions and methods for modulating apolipoprotein (a) expression
#1408Methods and compositions for treating inflammatory diseases
#1409Modulation of frataxin expression
#1410COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#1411Modulators of APOL1 expression
#1412TRANSCRIPTION MODULATION IN ANIMALS USING CRISPR/CAS SYSTEMS DELIVERED BY LIPID NANOPARTICLES
#1413ANTISENSE OLIGONUCLEOTIDES FOR RNA EDITING
#1414Inhibition of mir-22 miRNA by APT-110
#1415Antisense oligonucleotide compositions
#1416GUIDE RNA WITH CHEMICAL MODIFICATIONS
#1417CLEAVAGE-RESISTANT DONOR NUCLEIC ACIDS AND METHODS OF USE
#1418PHARMACEUTICAL COMPOSITION
#1419Methods and compositions for inhibiting expression of LDHA
#1420Interfering RNA molecules
#1421RNA interference in ocular indications
#1422Single stranded oligonucleotides inhibiting endocytosis
#1423Oligonucleotides for modulating TMEM106B expression
#1424Compositions Comprising Immune System Activators and Method of Using Same
#1425COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA
#1426SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
#1427Methods of treating spinal muscular atrophy
#1428Antisense molecules and methods for treating pathologies
#1429Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping
#1430Oligonucleotide compositions and methods thereof
#1431Nucleic acid complex, method for forming nucleic acid hybridization, pharmaceutical composition, nucleic acid probe, and complementary-strand nucleic acid complex
#1432Splice-switching oligonucleotides and methods of use
#1433Fully stabilized asymmetric siRNA
#1434Nuclease systems for genetic engineering
#1435COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#1436METHOD FOR ACTIVATING P21 GENE EXPRESSION
#1437COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#1438Modified tracrRNAs gRNAs, and uses thereof
#1439Nucleic acid aptamers to treat histone-induced disease states
#1440Inhibition of polyomavirus replication
#1441Nucleic acid molecules for pseudouridylation
#1442Methods and compositions for modulating apolipoprotein (a) expression
#1443Methods for modulating FMR1 expression
#1444LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS FOR SURVIVAL OF MOTOR NEURON (SMA) INHIBITORS
#1445Methods and compositions for macrophage polarization
#1446Antisense oligonucleotides rescue aberrant splicing of ABCA4
#1447Treatment of angiopoietin like 7 (ANGPTL7) related diseases
#1448Detection of microbial endotoxins in oral samples using aptamers
#1449Oligonucleotides matching COL7A1 exon 73 for epidermolysis bullosa therapy
#1450TMPRSS6 iRNA compositions and methods of use thereof
#1451Conjugated antisense compounds and their use
#1452RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1453Short interfering nucleic acid (siNA) compositions
#1454Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#1455Uses for prevention or treatment of brain diseases using microrna
#1456Method for screening splicing variants or events
#1457RNA-editing oligonucleotides and uses thereof
#1458Anti-C9ORF72 oligonucleotides and related methods
#1459Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#1460RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF
#1461CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
#1462METHOD FOR INCREASING FETAL HEMOGLOBIN EXPRESSION LEVEL
#1463COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE
#1464LAG3 binding peptides
#1465Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#1466USE OF SINGLE-STRANDED ANTISENSE OLIGONUCLEOTIDE IN PREVENTION OR TREATMENT OF GENETIC DISEASES INVOLVING A TRINUCLEOTIDE REPEAT EXPANSION
#1467METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
#1468OLIGONUCLEOTIDES FOR TISSUE SPECIFIC APOE MODULATION
#1469Compositions for modulating SOD-1 expression
#1470Modified RNAi agents
#1471Oligonucleotides for inducing paternal UBE3A expression
#1472Enzymatic methods to generate high yields of sequence specific rna with extreme precision
#1473COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1474Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof
#1475ASSAYS AND METHODS FOR DETERMINING EXPRESSION OF THE LECT2 GENE
#1476EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#1477High Specificity Genome Editing Using Chemically Modified Guide RNAs
#1478METHOD FOR IMPROVING FETAL HEMOGLOBIN EXPRESSION
#1479Methods for treating hepatitis B infection
#1480Methods for treating hepatitis B infection
#1481RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (SINA)
#1482ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES FROM PROTEINS
#1483Dual Targeting siRNA Agents
#1484GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
#1485Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
#1486Compositions and methods for modulating Ataxin 3 expression
#1487Engineered producer cell lines and methods of making and using the same
#1488Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
#1489Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
#1490Compositions and their uses directed to huntingtin
#1491RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
#1492LNA-G process
#1493Thiomorpholino oligonucleotides for the treatment of muscular dystrophy
#1494RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
#1495Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof
#1496Oligonucleotide compositions and methods thereof
#1497RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
#1498MODIFIED CPF1 GUIDE RNA
#1499Compositions and methods for inhibiting HMGB1 expression
#1500TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF